MLLCF (Molecular Partners AG) Total Assets: $111.34 Mil (As of Mar. 2026)


MLLCF Molecular Partners AG MLLCF
25 GF Score
Price $3.60
GF Value $0.51
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Total Assets?

Molecular Partners AG MLLCF 25 Total Assets is $111.34 Mil as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Molecular Partners AG's Total Assets for the quarter that ended in Mar. 2026 was $111.34 Mil.

During the past 12 months, Molecular Partners AG's average Total Assets Growth Rate was -12.80% per year. During the past 3 years, the average Total Assets Growth Rate was -11.60% per year. During the past 5 years, the average Total Assets Growth Rate was -17.40% per year. During the past 10 years, the average Total Assets Growth Rate was 9.20% per year.

During the past 13 years, Molecular Partners AG's highest 3-Year average Total Assets Growth Rate was 141.20%. The lowest was -38.90%. And the median was -8.45%.

Total Assets is connected with ROA %. Molecular Partners AG's annualized ROA % for the quarter that ended in Mar. 2026 was -55.77%. Total Assets is also linked to Revenue through Asset Turnover. Molecular Partners AG's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Molecular Partners AG  (OTCPK:MLLCF) Total Assets Explanation

Total Assets is connected with ROA %.

Molecular Partners AG's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-66.78/( (128.13+111.34)/ 2 )
=-66.78/119.735
=-55.77 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Molecular Partners AG's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (128.13+111.34)/ 2 )
=0/119.735
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Molecular Partners AG Total Assets Related Terms

Molecular Partners AG Total Assets Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Total Assets Chart

Molecular Partners AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 187.48 281.51 229.36 177.80 128.13

Molecular Partners AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.68 152.79 140.87 128.13 111.34
MLLCF
25GF Score
Molecular Partners AG MLLCF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Partners AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Molecular Partners AG's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=100.808+27.322
=128.13

Molecular Partners AG's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=86.945+24.395
=111.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $111.34 Mil mean?
Molecular Partners AG (MLLCF) has a Total Assets of $111.34 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Molecular Partners AG and its competitors.
Is Molecular Partners AG's Total Assets too high?
Molecular Partners AG's current Total Assets is $111.34 Mil. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Total Assets compare to VRTX and REGN?
Molecular Partners AG's Total Assets of $111.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Total Assets is $111.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.60 — trading 605.9% above its estimated fair value. The current Total Assets is $111.34 Mil. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Total Assets is $111.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (MLLCF) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of $3.60 is trading 605.9% above its estimated GF Value™ of $0.51. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for MLLCF:

  • Total Assets: $111.34 Mil
  • GF Value™: $0.51 vs. price of $3.60 (605.9% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score

Get the complete analysis for MLLCF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.60
Price
$0.51
GF Value